|
Rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in melanoma and lung cancer patients with autoimmune diseases. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Concerto HealthAI |
| |
|
No Relationships to Disclose |
| |
|
Leadership - American Cancer Society |
Honoraria - AstraZeneca; Elekta |
Consulting or Advisory Role - Abbvie; AstraZeneca; Doximity; Elekta; Merck |
Patents, Royalties, Other Intellectual Property - Wolters Kluwer |
Travel, Accommodations, Expenses - Abbvie; Elekta; Novocure |
| |
|
Employment - Decision Resources |
Leadership - Decision Resources |
Stock and Other Ownership Interests - Decision Resources |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbvie |